Top Markets
#1 CyberDEX CyberDEX +391.94%
#2 OVERTAKE OVERTAKE +60.20%
#3 deBridge deBridge +25.79%
#4 Clearpool Clearpool +25.70%
#5 Playnance Playnance +23.95%
#6 Nillion Nillion +21.37%
#7 B3 (Base) B3 (Base) +19.47%
#8 AUKI AUKI +15.74%
#9 龙虾 (Lobster) 龙虾 (Lobster) +15.62%
#10 Codatta Codatta +15.06%
Coin of the day
CyberDEX CyberDEX
Settings
Language
ENGLISH
Currency
USD
Theme
Nuformix plc Nuformix plc

Nuformix plc

NFX
Rank in Stocks #41013
Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes... Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes in developing therapies for fibrotic diseases and cancer, primarily through the innovative strategy of drug repurposing. Its current development portfolio includes NXP001, which has advanced beyond Phase 1 trials for application in oncology supportive care. Additionally, the company is progressing NXP004, a novel variant of Olaparib, currently in its intellectual property generation stage for oncological indications, and NXP002, which is undergoing pre-clinical evaluation for the treatment of idiopathic pulmonary fibrosis. Nuformix also holds an option agreement with Oxilio Ltd. concerning NXP001 for its oncology applications. Established in 2008, the company maintains its operational base in London.
Share Price
$0.00185055
Market Cap
$48.29K
Change (1 day)
-3.55%
Change (1 year)
30.31%
Country
GB
Trade Nuformix plc (NFX)

Category

Healthcare
Earnings for Nuformix plc (NFX)
Earnings in Mar 2026 TTM: $-857.89K
According to Nuformix plc latest financial reports the company's current earnings are $-857.89K. In 2024 the company made an earning of $-4.88M, a decrease compared to its 2023 earnings that were of $-754.56K. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Nuformix plc from 2014 to 2026
Earnings at the end of each year
Year Earnings Change
2026 (TTM) $-857.89K -3.39%
2025 $-888.01K -81.80%
2024 $-4.88M 546.72%
2023 $-754.56K -54.82%
2022 $-1.67M -11.94%
2021 $-1.90M 64.37%
2020 $-1.15M -51.92%
2019 $-2.40M -12.87%
2018 $-2.75M 220.48%
2017 $-859.40K 70.68%
2016 $-503.51K -206.04%
2014 $474.83K 0.00%
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -614,967.33%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 359,735.34%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B 468,046.88%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -227,477.01%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH